Pharmaceutical Market Trends, 2006-2010

리서치사	Urch Publishing, Ltd.
발행일	2006년 06월	상품코드	41779
페이지 정보	172 pages
가격	US $ 1,990 ￦ 2,370,200 PDF by E-mail (Single User License) US $ 2,100 ￦ 2,501,300 Hard Copy

한글목차
영문목차
관련자료

영문목차

Abstract

Pharmaceutical Market Trends, 2006: Key market forecasts & growth opportunities presents a detailed trend analysis of the global pharmaceutical market as at the end of 2005 and forecasts until 2010. The 170 page report presents a series of market forecasts and growth opportunities in order to help inform pharmaceutical decision-making, particularly in the areas of corporate planning, portfolio management and market forecasting.

The data and analysis contained within the report are comprehensive, consistent and up-to-date in order to provide a single-point reference for understanding key pharmaceutical market trends in 2006.

Headline Findings

The global pharmaceutical market is forecast to grow to US$842 billion in 2010, an equivalent CAGR of 6.9% over the next five years.
Strong growth in the 10 European markets that joined the European Union in 2004 will help to boost European sales over the next five years.
Of the leading product classes in 2005, cytostatics and angiotensin-II inhibitors generated the greatest year-on-year growth.
There were a total of 16 new blockbuster drugs in 2005, generating combined sales of US$18.1 billion.
Total pharmaceutical sales from the top 10 companies accounted for more than 40% of the total market.

Summary

Introduction
Key global markets
Key therapeutic markets
Key products
Key companies
Key trends and opportunities

Chapter 1. Introduction

Global pharmaceutical market
Report overview
- Methodology
- Sources
- Structure

Chapter 2. Key global markets

Key pharmaceutical markets
US pharmaceutical market
- US purchasing channels
- US retail drug market
- US therapy areas
- US market leaders
European pharmaceutical market
- European retail drug market
- European therapy areas
Japanese pharmaceutical market
- Japanese therapy areas

Chapter 3. Key therapeutic markets

Key therapy areas
- Retail drug therapy areas
Cardiovascular therapy area
- Cardiovascular markets
- Cardiovascular blockbusters
Central nervous system therapy area
- Central nervous system markets
- Central nervous system blockbusters
Alimentary/ metabolism therapy area
- Alimentary/ metabolism markets
- Alimentary/ metabolism blockbusters
Respiratory therapy area
- Respiratory markets
- Respiratory blockbusters
Anti-infectives therapy area
- Anti-infectives markets
- Anti-infectives blockbusters
Musculo-skeletal therapy area
- Musculo-skeletal markets
- Musculo-skeletal blockbusters
Cytostatics therapy area
- Cytostatics markets
- Cytostatics blockbusters

Chapter 4. Key products

Leading products
- Lipitor (atorvastatin)
- Plavix (clopidogrel)
- Advair/ Seretide (fluticasone; salmeterol)
- Norvasc (amlodipine)
- Nexium (esomeprazole)
- Zocor (simvastatin)
- Zyprexa (olanzapine)
- Prevacid (lansoprazole)
- Diovan/ Co-Diovan (valsartan/ hydrochlorothiazide)
- Enbrel (etanercept)
Blockbuster trends
- Blockbusters by drug type
- Blockbusters by therapy area
- Blockbusters by company

Chapter 5. Key companies

Major pharmaceutical companies
- Major company financials
- Major company locations
Top 10 pharmaceutical companies
- Top 10 company financials
- Top 10 company value drivers
Leading pharmaceutical companies
- Pfizer
- Sanofi-Aventis
- GlaxoSmithKline
- AstraZeneca
- Johnson and Johnson
- Roche
- Merck & Co
- Novartis
- Wyeth
- Bristol-Myers Squibb

Chapter 6. Key trends and opportunities

Global market forecasts
The US market
- The European market
- The Japanese market
- Other markets
Key therapy area forecasts
- Cardiovascular market
- Central nervous system market
- Alimentary/ metabolism market
- Anti-infectives market
- Respiratory market
Key product forecasts
- Lipitor (atorvastatin)
- Plavix (clopidogrel)
- Advair/ Seretide (fluticasone; salmeterol)
- Norvasc (amlodipine)
- Nexium (esomeprazole)
- Zocor (simvastatin)
- Zyprexa (olanzapine)
- Prevacid (lansoprazole)
- Diovan/ Co-Diovan (valsartan; hydrochlorothiazide)
- Enbrel (etanercept)
Key company forecasts
- Pfizer
- Sanofi-Aventis
- GlaxoSmithKline
- AstraZeneca
- Johnson and Johnson
- Roche
- Merck & Co
- Novartis
- Wyeth
- Bristol-Myers Squibb

Appendix

Proprietary data sources
- Product Trends Database
Company Trends Database
Top 100 pharmaceutical products
Top 64 pharmaceutical companies

List of Figures

Figure 1: Global pharmaceutical market, 1999-2005
Figure 2: Report structure
Figure 3: Global pharmaceutical market share by region, 2005
Figure 4: Global pharmaceutical market by region, 2003-2005
Figure 5: US pharmaceutical market, 2003-2005
Figure 6: US pharmaceutical market share by purchasing channel,
Figure 7: US pharmaceutical market by purchasing channel, 2003-
Figure 8: US retail pharmaceutical market, 2003-2005
Figure 9: US retail pharmaceutical market share by therapy area, 2005
Figure 10: US retail pharmaceutical market by therapy area, 2003-2005
Figure 11: Top 10 products by US pharmaceutical sales, 2005
Figure 12: Top 10 companies by US pharmaceutical sales,
Figure 13: Top 10 companies by share of US pharmaceutical sales,
Figure 14: European pharmaceutical market, 2003-2005
Figure 15: European pharmaceutical market share by country, 2005
Figure 16: European top 5 retail pharmaceutical market, 2003-2005
Figure 17: European top 5 retail pharmaceutical market share by country, 2005
Figure 18: European top 5 retail pharmaceutical market by country, 2003-2005
Figure 19: European top 5 retail pharmaceutical market share by therapy area, 2005
Figure 20: European top 5 retail pharmaceutical market by therapy area, 2003-2005
Figure 21: Japanese pharmaceutical market, 2003-2005
Figure 22: Japanese pharmaceutical market share by therapy area, 2005
Figure 23: Japanese pharmaceutical market by therapy area, 2003-2005
Figure 24: Global pharmaceutical market by therapy area, 2005
Figure 25: Top 10 product classes by global pharmaceutical sales, 2005
Figure 26: Global retail pharmaceutical market share by therapy area, 2005
Figure 27: Global retail pharmaceutical market by therapy area, 2003-
Figure 28: Cardiovascular retail pharmaceutical market, 2003-2005
Figure 29: Cardiovascular retail pharmaceutical market share by country, 2005
Figure 30: Cardiovascular retail pharmaceutical market by country, 2003-2005
Figure 31: Central nervous system retail pharmaceutical market, 2003-2005
Figure 32: Central nervous system retail pharmaceutical market share by country, 2005
Figure 33: Central nervous system retail pharmaceutical market by country, 2003-2005
Figure 34: Alimentary/ metabolism retail pharmaceutical market, 2003-2005
Figure 35: Alimentary/ metabolism retail pharmaceutical market share by country, 2005
Figure 36: Alimentary/ metabolism retail pharmaceutical market by country, 2003-2005
Figure 37: Respiratory retail pharmaceutical market, 2003-2005
Figure 38: Respiratory retail pharmaceutical market share by country, 2005
Figure 39: Respiratory retail pharmaceutical market by country, 2003-2005
Figure 40: Anti-infectives retail pharmaceutical market, 2003-2005
Figure 41: Anti-infectives retail pharmaceutical market share by country, 2005
Figure 42: Anti-infectives retail pharmaceutical market by country, 2003-2005
Figure 43: Musculo-skeletal retail pharmaceutical market, 2003-2005
Figure 44: Musculo-skeletal retail pharmaceutical market share by country, 2005
Figure 45: Musculo-skeletal retail pharmaceutical market by country, 2003-2005
Figure 46: Cytostatics retail pharmaceutical market, 2003-2005
Figure 47: Cytostatics retail pharmaceutical market share by country, 2005
Figure 48: Cytostatics retail pharmaceutical market by country, 2003-2005
Figure 49: Blockbuster drug sales share by drug type, 2005
Figure 50: Blockbuster drug sales share by lifecycle stage, 2005
Figure 51: Blockbuster drug sales share by therapy area, 2005
Figure 52: Blockbuster drug sales share by company, 2005
Figure 53: Major companies pharmaceutical sales, 2003-2005
Figure 54: Major companies revenue share allocation, 2005
Figure 55: Major companies revenue allocation, 2003-2005
Figure 56: Major companies pharmaceutical sales by location, 2005
Figure 57: Top 10 pharma companies pharmaceutical sales, 2003-2005
Figure 58: Top 10 pharma companies by global pharmaceutical sales, 2005
Figure 59: Top 10 biotechnology companies by global revenues, 2005
Figure 60: Top 10 pharma companies revenue share allocation, 2005
Figure 61: Top 10 pharma companies revenue allocation, 2003-2005
Figure 62: Key value drivers for top 10 pharma companies (income), 2005
Figure 63: Key value drivers for top 10 pharma companies (sales), 2005
Figure 64: Key value drivers for top 10 pharma companies (sales/ R&D), 2005
Figure 65: Pfizer therapy area sales, 2003-2005
Figure 66: Sanofi-Aventis blockbuster therapy area sales, 2003-2005
Figure 67: GlaxoSmithKline therapy area sales, 2003-2005
Figure 68: AstraZeneca therapy area sales, 2003-2005
Figure 69: Johnson and Johnson blockbuster therapy area sales, 2003-2005
Figure 70: Roche therapy area sales, 2003-2005
Figure 71: Merck & Co blockbuster therapy area sales, 2003-2005
Figure 72: Novartis therapy area sales, 2003-2005
Figure 73: Wyeth blockbuster therapy area sales, 2003-2005
Figure 74: Bristol-Myers Squibb therapy area sales, 2005
Figure 75: Global pharmaceutical market forecast, 2003-2010
Figure 76: Global pharmaceutical market forecast by regions, 2003-2010
Figure 77: Top 10 pharmaceutical drugs by forecast sales, 2010
Figure 78: Lipitor (atorvastatin) forecast sales, 2003-2010
Figure 79: Plavix (clopidogrel) forecast sales, 2003-2010
Figure 80: Advair/ Seretide (fluticasone; salmeterol) forecast sales, 2003-
Figure 81: Norvasc (amlodipine) forecast sales, 2003-2010
Figure 82: Nexium (esomeprazole) forecast sales, 2003-2010
Figure 83: Zocor (simvastatin) forecast sales, 2003-2010
Figure 84: Zyprexa (olanzapine) forecast sales, 2003-2010
Figure 85: Prevacid (lansoprazole) forecast sales, 2003-2010
Figure 86: Diovan/ Co-Diovan (valsartan; hydrochlorothiazide) forecast sales, 2003-2010
Figure 87: Enbrel (etanercept) forecast sales, 2003-2010

List Of Tables

Table 1: Global pharmaceutical market trends by region, 2003-2005
Table 2: US pharmaceutical market trends by purchasing channel, 2003-2005
Table 3: US retail pharmaceutical market trends by therapy area, 2003-2005
Table 4: Top 10 products trends by US pharmaceutical sales, 2003-2005
Table 5: European top 5 retail pharmaceutical market trends by country, 2003-2005
Table 6: European top 5 retail pharmaceutical market trends by therapy area, 2003-2005
Table 7: Japanese pharmaceutical market trends by therapy area, 2003-2005
Table 8: Top 10 product classes trends by global pharmaceutical sales, 2004-2005
Table 9: Global retail pharmaceutical market trends by therapy area, 2003-2005
Table 10: Cardiovascular retail pharmaceutical market trends by country, 2003-2005
Table 11: Cardiovascular blockbuster drug sales, 2003-2005
Table 12: Central nervous system retail pharmaceutical market trends by country, 2003-2005
Table 13: Central nervous system blockbuster drug sales, 2003-2005
Table 14: Alimentary/ metabolism retail pharmaceutical market trends by country, 2003-2005
Table 15: Alimentary/ metabolism blockbuster drug sales, 2003-2005
Table 16: Respiratory retail pharmaceutical market trends by country, 2003-2005
Table 17: Respiratory blockbuster drug sales, 2003-2005
Table 18: Anti-infectives retail pharmaceutical market trends by country, 2003-2005
Table 19: Anti-infectives blockbuster drug sales, 2003-2005
Table 20: Musculo-skeletal retail pharmaceutical market trends by country, 2003-2005
Table 21: Musculo-skeletal blockbuster drug sales, 2003-2005
Table 22: Cytostatics retail pharmaceutical market trends by country, 2003-2005
Table 23: Cytostatics blockbuster drug sales, 2003-2005
Table 24: Top 20 products by global pharmaceutical sales, 2003-2005
Table 25: Lipitor (atorvastatin) profile, 2005
Table 26: Plavix (clopidogrel) profile, 2005
Table 27: Advair/ Seretide (fluticasone; salmeterol) profile, 2005
Table 28: Norvasc (amlodipine) profile, 2005
Table 29: Nexium (esomeprazole) profile, 2005
Table 30: Zocor (simvastatin) profile, 2005
Table 31: Zyprexa (olanzapine) profile, 2005
Table 32: Prevacid (lansoprazole) profile, 2005
Table 33: Diovan/ Co-Diovan (valsartan/ hydrochlorothiazide) profile, 2005
Table 34: Enbrel (etanercept) profile, 2005
Table 35: Top 10 blockbuster products by global pharmaceutical sales growth, 2003-2005
Table 36: Top 10 blockbuster products by declining global pharmaceutical sales, 2003-2005
Table 37: New blockbuster products, 2003-2005
Table 38: Major companies revenue allocation trends, 2003-2005
Table 39: Top 10 pharma companies by global pharmaceutical sales, 2003-2005
Table 40: Top 10 biotechnology companies by global revenues, 2003-2005
Table 41: Top 10 pharma companies revenue allocation trends, 2003-2005
Table 42: Pfizer profile, 2005
Table 43: Pfizer blockbuster sales, 2003-2005
Table 44: Sanofi-Aventis profile, 2005
Table 45: Sanofi-Aventis blockbuster sales, 2003-2005
Table 46: GlaxoSmithKline profile, 2005
Table 47: GlaxoSmithKline blockbuster sales, 2003-2005
Table 48: AstraZeneca profile, 2005
Table 49: AstraZeneca blockbuster sales, 2003-2005
Table 50: Johnson and Johnson profile, 2005
Table 51: Johnson and Johnson blockbuster sales, 2003-2005
Table 52: Roche profile, 2005
Table 53: Roche blockbuster sales, 2003-2005
Table 54: Merck & Co profile, 2005
Table 55: Merck & Co blockbuster sales, 2003-2005
Table 56: Novartis profile, 2005
Table 57: Novartis blockbuster sales, 2003-2005
Table 58: Wyeth profile, 2005
Table 59: Wyeth blockbuster sales, 2003-2005
Table 60: Bristol-Myers Squibb profile, 2005
Table 61: Bristol-Myers Squibb blockbuster sales, 2003-2005
Table 62: Global pharmaceutical market forecast by regions, 2003-2010
Table 63: Global pharmaceutical market forecast by therapy area, 2005-2010
Table 64: Top 10 pharmaceutical drugs forecast, 2003-2010
Table 65: Top 10 pharmaceutical companies forecast, 2005-2010
Table 66: Top 100 products by global pharmaceutical sales, 2003-2005
Table 67: Top 64 companies by global pharmaceutical sales, 2003-2005